Genes, proteins, and neurotoxins involved in Parkinson's disease

Progress in Neurobiology

Volumn 73, Issue 3, 2004, Pages 151-177

  v Bohlen und Halbach, Oliver ^a   Schober, A ^a   Krieglstein, K ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

6 hydroxydopamine; 6 OHDA; AD; Alzheimer's disease; AR JP; autosomal recessive juvenile parkinsonism; CDCrel 1; cell division control related protein 1; central nervous system; CNS; DA; DAergic; dementia with Lewy bodies; DLB; DOPAL; dopamine; dopaminergic

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMANTADINE; ANNONACIN; CALCIUM CHANNEL BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; IRON CHELATING AGENT; LEVODOPA; MANEB; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTOXIN; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDOPAMINE; PARAQUAT; PARKIN; PROTEIN DERIVATIVE; PROTEIN DORFIN; ROTENONE; SCAVENGER; SYNPHILIN 1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

BRAIN NERVE CELL; CELL DEATH; CELL INCLUSION; CELL LOSS; CLINICAL FEATURE; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; GENE LOCUS; GENE MUTATION; GENETIC MANIPULATION; HEREDITY; HUMAN; LEWY BODY; MEDICAL RESEARCH; MORPHOLOGY; NEURITE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; ANTIGENS, CD45; CARRIER PROTEINS; CELL DEATH; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HUMANS; NERVE TISSUE PROTEINS; NEUROTOXINS; PARKINSON DISEASE; SYNUCLEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 3242695252     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2004.05.002     Document Type: Review

References (304)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 25:2000;239-252
2. Ahmadi F.A., Linseman D.A., Grammatopoulos T.N., Jones S.M., Bouchard R.J., Freed C.R., Heidenreich K.A., Zawada W.M. The pesticide rotenone induces caspase-3-mediated apoptosis in ventral mesencephalic dopaminergic neurons. J. Neurochem. 87:2003;914-921
3. Alam M., Schmidt W.J. Rotenone destroys dopaminergic neurons and induces Parkinsonian symptoms in rats. Behav. Brain Res. 136:2002;317-324
4. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., Halliwell B. Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69:1997;1196-1203
5. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., Watson, J.D., 1987. Molekularbiologie der Zelle. VCH, Weinheim, Germany.
6. Andringa G., Du F., Chase T.N., Bennett M.C. Mapping of rat brain using the synuclein-1 monoclonal antibody reveals somatodendritic expression of alpha-synuclein in populations of neurons homologous to those vulnerable to Lewy body formation in human synucleopathies. J. Neuropathol. Exp. Neurol. 62:2003;1060-1075
7. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12:1997;25-31
8. Auluck P.K., Bonini N.M. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8:2002;1185-1186
9. Banati R.B., Daniel S.E., Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13:1998;221-227
10. Bandopadhyay R., de Silva R., Khan N., Graham E., Vaughan J., Engelender S., Ross C., Morris H., Morris C., Wood N.W., Daniel S., Lees A. No pathogenic mutations in the synphilin-1 gene in Parkinson's disease. Neurosci. Lett. 307:2001;125-127
11. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology. 61:2003;293-296
12. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2:2001;325-334
13. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555
14. Berger K., Przedborski S., Cadet J.L. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res. Bull. 26:1991;301-307
15. Betarbet R., Sherer T.B., Greenamyre J.T. Animal models of Parkinson's disease. Bioessays. 24:2002;308-318
16. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1306
17. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155:1999;268-273
18. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N. Jr., Chen J.F., Schwarzschild M.A., Chase T.N. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184:2003;285-294
19. Bonifati V., Breedveld G.J., Squitieri F., Vanacore N., Brustenghi P., Harhangi B.S., Montagna P., Cannella M., Fabbrini G., Rizzu P., Van Duijn C.M., Oostra B.A., Meco G., Heutink P. Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann. Neurol. 51:2002;253-256
20. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., Van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 299:2003;256-259
21. Braak E., Sandmann-Keil D., Rub U., Gai W.P., de Vos R.A., Steur E.N., Arai K., Braak H. alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. (Berl.). 101:2001;195-201
22. Braak H., Del Tredici K., Bratzke H., Hamm-Clement J., Sandmann-Keil D., Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 249(Suppl. 3):2002;1-5
23. Braak H., Tredici K.D., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24:2003;197-211
24. Bradbury J. Alpha-synuclein gene triplication discovered in Parkinson's disease. Lancet Neurol. 2:2003;715
25. Bringmann G., Bruckner R., Mossner R., Feineis D., Heils A., Lesch K.P. Effect of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) on human serotonergic cells. Neurochem. Res. 25:2000;837-843
26. Bringmann G., God R., Feineis D., Wesemann W., Riederer P., Rausch W.D., Reichmann H., Sontag K.H. The TaClo concept: 1-trichloromethyl-1,2,3,4- tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. J. Neural. Transm. Suppl. 46:1995;235-244
27. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 823:1999;1-10
28. Burke W.J. 3,4-Dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease. Curr. Drug Target CNS Neurol. Disord. 2:2003;143-148
29. Bushnell D.M., Martin M.L. Quality of life and Parkinson's disease: translation and validation of the US Parkinson's disease questionnaire (PDQ-39). Qual. Life Res. 8:1999;345-350
30. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIlwain K.L., Orrison B., Chen A., Ellis C.E., Paylor R., Lu B., Nussbaum R.L. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22:2002;8797-8807
31. Caparros-Lefebvre D., Elbaz A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. Lancet. 354:1999;281-286
32. Cardellach F., Marti M.J., Fernandez-Sola J., Marin C., Hoek J.B., Tolosa E., Urbano-Marquez A. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology. 43:1993;2258-2262
33. Cenci M.A., Whishaw I.Q., Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3:2002;574-579
34. Champy P., Hoglinger G.U., Feger J., Gleye C., Hocquemiller R., Laurens A., Guerineau V., Laprevote O., Medja F., Lombes A., Michel P.P., Lannuzel A., Hirsch E.C., Ruberg M. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J. Neurochem. 88:2004;63-69
35. Chase T.N., Bibbiani F., Bara-Jimenez W., Dimitrova T., Oh-Lee J.D. Translating A2A antagonist KW6002 from animal models to Parkinsonian patients. Neurology. 61:2003;S107-S111
36. Chase T.N., Oh J.D., Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology. 51:1998;S30-S35
37. Chung K.K., Dawson V.L., Dawson T.M. The role of the ubiquitin- proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. TINS. 24:2001a;S7-S14
38. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., Ross C.A., Dawson V.L., Dawson T.M. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7:2001b;1144-1150
39. Ciechanover A. Linking ubiquitin, parkin and synphilin-1. Nat. Med. 7:2001;1108-1109
40. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. TINS. 21:1998;249-254
41. Cleeter M.W., Cooper J.M., Darley-Usmar V.M., Moncada S., Schapira A.H. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett. 345:1994;50-54
42. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4:1998;1318-1320
43. Corasaniti M.T., Strongoli M.C., Rotiroti D., Bagetta G., Nistico G. Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. Pharmacol. Toxicol. 83:1998;1-7
44. Crosby, N.J., Deane, K.H., Clarke, C.E., 2003. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst. Rev. CD003467.
45. Crossman A.R., Peggs D., Boyce S., Luquin M.R., Sambrook M.A. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology. 28:1989;1271-1273
46. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 122:1999;1437-1448
47. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., Hen R. Resistance of alpha-synuclein null mice to the Parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A. 99:2002;14524-14529
48. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273:1998;9443-9449
49. Dawson T.M. New animal models for Parkinson's disease. Cell. 101:2000;115-118
50. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 302:2003;819-822
51. Dawson V.L., Dawson T.M. Nitric oxide neurotoxicity. J. Chem. Neuroanat. 10:1996;179-190
52. Del Tredici K., Rub U., de Vos R.A., Bohl J.R., Braak H. Where does parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61:2002;413-426
53. Dev K.K., van der P.H., Sommer B., Rovelli G. Part I. Parkin-associated proteins and Parkinson's disease. Neuropharmacology. 45:2003;1-13
54. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9:1994a;92-97
55. Dexter D.T., Sian J., Rose S., Hindmarsh J.G., Mann V.M., Cooper J.M., Wells F.R., Daniel S.E., Lees A.J., Schapira A.H. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35:1994b;38-44
56. Difazio M.C., Hollingsworth Z., Young A.B., Penney J.B. Jr. Glutamate receptors in the substantia nigra of Parkinson's disease brains. Neurology. 42:1992;402-406
57. Djaldetti R., Melamed E. New drugs in the future treatment of Parkinson's disease. J. Neurol. 249:2002;II30-II35
58. Dong Z., Ferger B., Paterna J.C., Vogel D., Furler S., Osinde M., Feldon J., Bueler H. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein. CDCrel-1. Proc. Natl. Acad. Sci. U.S.A. 100:2003;12438-12443
59. Dunnett S.B., Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature. 399:1999;A32-A39
60. Elbaz A., Levecque C., Clavel J., Vidal J.S., Richard F., Correze J.R., Delemotte B., Amouyel P., Alperovitch A., Chartier-Harlin M.C., Tzourio C. S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. Mov. Disord. 18:2003;130-137
61. Eliezer D., Kutluay E., Bussell R. Jr., Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307:2001;1061-1073
62. Engelender S., Kaminsky Z., Guo X., Sharp A.H., Amaravi R.K., Kleiderlein J.J., Margolis R.L., Troncoso J.C., Lanahan A.A., Worley P.F., Dawson V.L., Dawson T.M., Ross C.A. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22:1999;110-114
63. Engelender S., Wanner T., Kleiderlein J.J., Wakabayashi K., Tsuji S., Takahashi H., Ashworth R., Margolis R.L., Ross C.A. Organization of the human synphilin-1 gene, a candidate for Parkinson's disease. Mamm. Genome. 11:2000;763-766
64. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D., Forno L., Gwinn-Hardy K., Petrucelli L., Hussey J., Singleton A., Tanner C., Hardy J., Langston J.W. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50:2001;293-300
65. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., Maraganore D., Gwinn-Hardy K., Wszolek Z., Dickson D., Langston J.W. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55:2004;174-179
66. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature. 404:2000;394-398
67. Ferrante R.J., Schulz J.B., Kowall N.W., Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 753:1997;157-162
68. Ferrarese C., Tremolizzo L., Rigoldi M., Sala G., Begni B., Brighina L., Ricci G., Albizzati M.G., Piolti R., Crosti F., Dalpra L., Frattola L. Decreased platelet glutamate uptake and genetic risk factors in patients with Parkinson's disease. Neurol. Sci. 22:2001;65-66
69. Ferraz H.B., Bertolucci P.H., Pereira J.S., Lima J.G., Andrade L.A. Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication. Neurology. 38:1988;550-553
70. Foley P., Riederer P. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J. Neurol. 247(Suppl. 2):2000;II82-II94
71. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55:1996;259-272
72. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4:2002;160-164
73. Fukushima T., Tawara T., Isobe A., Hojo N., Shiwaku K., Yamane Y. Radical formation site of cerebral complex I and Parkinson's disease. J. Neurosci. Res. 42:1995;385-390
74. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51:2002;296-301
75. Galvin J.E., Lee V.M., Trojanowski J.Q. Synucleinopathies: clinical and pathological implications. Arch. Neurol. 58:2001a;186-190
76. Galvin J.E., Schuck T.M., Lee V.M., Trojanowski J.Q. Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra. Exp. Neurol. 168:2001b;347-355
77. George J.M., Jin H., Woods W.S., Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 15:1995;361-372
78. Giasson B.I., Duda J.E., Forman M.S., Lee V.M., Trojanowski J.Q. Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. Exp. Neurol. 172:2001;354-362
79. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 290:2000;985-989
80. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 34:2002;521-533
81. Giasson B.I., Lee V.M. Parkin and the molecular pathways of Parkinson's disease. Neuron. 31:2001;885-888
82. Gibb W.R. Neuropathology of the substantia nigra. Eur. Neurol. 31:1991;48-59
83. Gibb W.R., Scott T., Lees A.J. Neuronal inclusions of Parkinson's disease. Mov. Disord. 6:1991;2-11
84. Giovanni A., Sieber B.A., Heikkila R.E., Sonsalla P.K. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Part 1. Systemic administration. J. Pharmacol. Exp. Ther. 270:1994a;1000-1007
85. Giovanni A., Sonsalla P.K., Heikkila R.E. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2. Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 270:1994b;1008-1014
86. Godwin-Austen R.B., Frears C.C., Bergmann S., Parkes J.D., Knill-Jones R.P. Combined treatment of parkinsonism with L-DOPA and amantadine. Lancet. 2:1970;383-385
87. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2:2001;492-501
88. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., Gajendiran M., Roth B.L., Chesselet M.F., Maidment N.T., Levine M.S., Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278:2003;43628-43635
89. Goldberg M.S., Lansbury P.T. Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2:2000;E115-E119
90. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 50:1998;1346-1350
91. Greenamyre J.T., Eller R.V., Zhang Z., Ovadia A., Kurlan R., Gash D.M. AntiParkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35:1994;655-661
92. Greenamyre J.T., MacKenzie G., Peng T.I., Stephans S.E. Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66:1999;85-97
93. Grunblatt E., Mandel S., Youdim M.B. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J. Neurol. 247:2000;II95-II102
94. Gu W.J., Abbas N., Lagunes M.Z., Parent A., Pradier L., Bohme G.A., Agid Y., Hirsch E.C., Raisman-Vozari R., Brice A. Cloning of rat parkin cDNA and distribution of parkin in rat brain. J. Neurochem. 74:2000;1773-1776
95. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., Shults C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37:1995;714-722
96. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or fiction? Ann. Neurol. 32:1992;S10-S15
97. Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R.T., Beal M.F. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2:1996;1017-1021
98. Harhangi B.S., Farrer M.J., Lincoln S., Bonifati V., Meco G., De Michele G., Brice A., Durr A., Martinez M., Gasser T., Bereznai B., Vaughan J.R., Wood N.W., Hardy J., Oostra B.A., Breteler M.M. The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. Neurosci. Lett. 270:1999;1-4
99. Hashimoto M., Takenouchi T., Rockenstein E., Masliah E. Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J. Neurochem. 85:2003;1468-1479
100. Heikkila R.E., Nicklas W.J., Vyas I., Duvoisin R.C. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine toxicity. Neurosci. Lett. 62:1985;389-394
101. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479
102. Hishikawa N., Niwa J., Doyu M., Ito T., Ishigaki S., Hashizume Y., Sobue G. Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis. Am. J. Pathol. 163:2003;609-619
103. Hoglinger G.U., Feger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84:2003;491-502
104. Hong L., Ko H.W., Gwag B.J., Joe E., Lee S., Kim Y.T., Suh Y.H. The cDNA cloning and ontogeny of mouse alpha-synuclein. NeuroReport. 9:1998;1239-1243
105. Horowitz J.M., Myers J., Stachowiak M.K., Torres G. Identification and distribution of Parkin in rat brain. NeuroReport. 10:1999;3393-3397
106. Horowitz J.M., Vernace V.A., Myers J., Stachowiak M.K., Hanlon D.W., Fraley G.S., Torres G. Immunodetection of parkin protein in vertebrate and invertebrate brains: a comparative study using specific antibodies. J. Chem. Neuroanat. 21:2001;75-93
107. Ikonomidou C., Turski L. Neurodegenerative disorders: clues from glutamate and energy metabolism. Crit. Rev. Neurobiol. 10:1996;239-263
108. Imai Y., Soda M., Hatakeyama S., Akagi T., Hashikawa T., Nakayama K.I., Takahashi R. CHIP is associated with parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell. 10:2002;55-67
109. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell. 105:2001;891-902
110. Imai Y., Soda M., Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275:2000;35661-35664
111. Impey S., Obrietan K., Storm D.R. Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. Neuron. 23:1999;11-14
112. Ito T., Niwa J., Hishikawa N., Ishigaki S., Doyu M., Sobue G. Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1. J. Biol. Chem. 278:2003;29106-29114
113. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron. 14:1995;467-475
114. Iwata A., Maruyama M., Akagi T., Hashikawa T., Kanazawa I., Tsuji S., Nukina N. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum. Mol. Genet. 12:2003;2625-2635
115. Iwatsubo T. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. J. Neurol. 250:2003;III11-III14
116. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:1995;257-269
117. Janetzky B., God R., Bringmann G., Reichmann H. 1-Trichloromethyl-1,2,3, 4-tetrahydro-beta-carboline, a new inhibitor of complex I. J. Neural. Transm. Suppl. 46:1995;265-273
118. Javitch J.A., Snyder S.H. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur. J. Pharmacol. 106:1984;455-456
119. Jellinger K.A. Cell death mechanisms in Parkinson's disease. J. Neural. Trans. 107:2000;1-29
120. Jellinger K.A. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution - a pilot study. Acta Neuropathol. (Berl.). 106:2003;191-201
121. Jenco J.M., Rawlingson A., Daniels B., Morris A.J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry. 37:1998;4901-4909
122. Jenner P. Parkinson's disease, pesticides and mitochondrial dysfunction. TINS. 24:2001;245-247
123. Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology. 61:2003a;S32-S38
124. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53:2003b;S26-S36
125. Jensen P.H., Hojrup P., Hager H., Nielsen M.S., Jacobsen L., Olesen O.F., Gliemann J., Jakes R. Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. Biochem. J. 323:1997;539-546
126. Jeon B.S., Jackson-Lewis V., Burke R.E. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration. 4:1995;131-137
127. Jin H., Clayton D.F. Synelfin regulation during the critical period for song learning in normal and isolated juvenile zebra finches. Neurobiol. Learn Mem. 68:1997;271-284
128. Joazeiro C.A., Weissman A.M. RING finger proteins: mediators of ubiquitin ligase activity. Cell. 102:2000;549-552
129. Junn E., Mouradian M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320:2002;146-150
130. Kahle P.J., Haass C., Kretzschmar H.A., Neumann M. Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J. Neurochem. 82:2002;449-457
131. Kase H., Aoyama S., Ichimura M., Ikeda K., Ishii A., Kanda T., Koga K., Koike N., Kurokawa M., Kuwana Y., Mori A., Nakamura J., Nonaka H., Ochi M., Saki M., Shimada J., Shindou T., Shiozaki S., Suzuki F., Takeda M., Yanagawa K., Richardson P.J., Jenner P., Bedard P., Borrelli E., Hauser R.A., Chase T.N. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology. 61:2003;S97-S100
132. Katsuse O., Iseki E., Marui W., Kosaka K. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J. Neurol. Sci. 211:2003;29-35
133. Kawamata H., McLean P.J., Sharma N., Hyman B.T. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. J. Neurochem. 77:2001;929-934
134. Kessler J.C., Rochet J.C., Lansbury P.T. Jr. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. Biochemistry. 42:2003;672-678
135. Kholodilov N.G., Neystat M., Oo T.F., Lo S.E., Larsen K.E., Sulzer D., Burke R.E. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J. Neurochem. 73:1999;2586-2599
136. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22:2002;2780-2791
137. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608
138. Kitada T., Asakawa S., Minoshima S., Mizuno Y., Shimizu N. Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm. Genome. 11:2000;417-421
139. Klein C. The genetics of Parkinson syndrome. Schweiz Rundsch Med. Prax. 90:2001;1015-1023
140. Klein C., Pramstaller P.P., Kis B., Page C.C., Kann M., Leung J., Woodward H., Castellan C.C., Scherer M., Vieregge P., Breakefield X.O., Kramer P.L., Ozelius L.J. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann. Neurol. 48:2000;65-71
141. Klein R.L., King M.A., Hamby M.E., Meyer E.M. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13:2002;605-612
142. Kornhuber J., Weller M., Schoppmeyer K., Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural. Transm. Suppl. 43:1994;91-104
143. Kotake Y., Ohta S. MPP(+) analogs acting on mitochondria and inducing neuro-degeneration. Curr. Med. Chem. 10:2003;2507-2516
144. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. NeuroReport. 11:2000;211-213
145. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:1998;106-108
146. Kuhn K., Wellen J., Link N., Maskri L., Lubbert H., Stichel C.C. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur. J. Neurosci. 17:2003;1-12
147. Kurihara L.J., Kikuchi T., Wada K., Tilghman S.M. Loss of Uch-L1 and Uch-L3 leads to neurodegeneration, posterior paralysis and dysphagia. Hum. Mol. Genet. 10:2001;1963-1970
148. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980
149. Lannuzel A., Michel P.P., Hoglinger G.U., Champy P., Jousset A., Medja F., Lombes A., Darios F., Gleye C., Laurens A., Hocquemiller R., Hirsch E.C., Ruberg M. The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience. 121:2003;287-296
150. Lansbury P.T. Jr., Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Cell Biol. 14:2002;653-660
151. Larsen C.N., Krantz B.A., Wilkinson K.D. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry. 37:1998;3358-3368
152. Larsen C.N., Price J.S., Wilkinson K.D. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry. 35:1996;6735-6744
153. Lavedan C. The synuclein family. Genome Res. 8:1998;871-880
154. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8968-8973
155. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452
156. Li J.Y., Henning J.P., Dahlstrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience. 113:2002;463-478
157. Lincoln S., Vaughan J., Wood N., Baker M., Adamson J., Gwinn-Hardy K., Lynch T., Hardy J., Farrer M. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. NeuroReport. 10:1999;427-429
158. Lindner M.D., Cain C.K., Plone M.A., Frydel B.R., Blaney T.J., Emerich D.F., Hoane M.R. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav. Brain Res. 102:1999;1-16
159. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., Chen R.C. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology. 48:1997;1583-1588
160. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 111:2002;209-218
161. + toxicity encodes a vesicular amine transporter. Cell. 70:1992;539-551
162. Lo B.C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 99:2002;10813-10818
163. Lockhart P.J., Holtom B., Lincoln S., Hussey J., Zimprich A., Gasser T.,
164. Lotharius J., Brundin P. Pathogenesis of parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3:2002;932-942
165. Lowe J., McDermott H., Landon M., Mayer R.J., Wilkinson K.D. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161:1990;153-160
166. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B.S., Meco G., Denefle P., Wood N.W., Agid Y., Brice A. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 342:2000;1560-1567
167. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277:2002;1641-1644
168. Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M., Di Monte D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 23:2003;3095-3099
169. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology. 53:1999;1858-1860
170. Maries E., Dass B., Collier T.J., Kordower J.H., Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 4:2003;727-738
171. Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8:1988;2804-2815
172. Maroteaux L., Scheller R.H. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 11:1991;335-343
173. Marti M.J., Tolosa E., Campdelacreu J. Clinical overview of the synucleinopathies. Mov. Disord. 18(Suppl. 6):2003;21-27
174. Marx F.P., Holzmann C., Strauss K.M., Li L., Eberhardt O., Gerhardt E., Cookson M.R., Hernandez D., Farrer M.J., Kachergus J., Engelender S., Ross C.A., Berger K., Schols L., Schulz J.B., Riess O., Kruger R. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum. Mol. Genet. 12:2003;1223-1231
175. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287:2000;1265-1269
176. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., Mucke L. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;12245-12250
177. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., Di Monte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10:2002;119-127
178. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., Olanow C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81:2002;301-306
179. Meco G., Bonifati V., Vanacore N., Fabrizio E. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scand. J. Work Environ. Health. 20:1994;301-305
180. Menegon A., Board P.G., Blackburn A.C., Mellick G.D., Le Couteur D.G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet. 352:1998;1344-1346
181. Mizuno Y., Hattori N., Kitada T., Matsumine H., Mori H., Shimura H., Kubo S., Kobayashi H., Asakawa S., Minoshima S., Shimizu N. Familial Parkinson's disease. Alpha-synuclein and parkin. Adv. Neurol. 86:2001a;13-21
182. Mizuno Y., Hattori N., Mori H., Suzuki T., Tanaka K. Parkin and Parkinson's disease. Curr. Opin. Neurol. 14:2001b;477-482
183. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163:1989;1450-1455
184. 2+ release. Trends Pharmacol. Sci. 16:1995;356-359
185. Mori F., Tanji K., Yoshimoto M., Takahashi H., Wakabayashi K. Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system. Brain Res. 941:2002;118-126
186. Mori H., Kondo T., Yokochi M., Matsumine H., Nakagawa-Hattori Y., Miyake T., Suda K., Mizuno Y. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology. 51:1998;890-892
187. Murray I.J., Medford M.A., Guan H.P., Rueter S.M., Trojanowski J.Q., Lee V.M. Synphilin in normal human brains and in synucleinopathies: studies with new antibodies. Acta Neuropathol. (Berl.). 105:2003;177-184
188. Nagano Y., Yamashita H., Takahashi T., Kishida S., Nakamura T., Iseki E., Hattori N., Mizuno Y., Kikuchi A., Matsumoto M. Siah-1 facilitates ubiquitination and degradation of synphilin-1. J. Biol. Chem. 278:2003;51504-51514
189. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural. Transm. Suppl. 60:2000;277-290
190. Neumann M., Kahle P.J., Giasson B.I., Ozmen L., Borroni E., Spooren W., Muller V., Odoy S., Fujiwara H., Hasegawa M., Iwatsubo T., Trojanowski J.Q., Kretzschmar H.A., Haass C. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110:2002;1429-1439
191. Nicholls D.G., Budd S.L. Neuronal excitotoxicity: the role of mitochondria. Biofactors. 8:1998;287-299
192. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508
193. + and mitochondrial function. Life Sci. 40:1987;721-729
194. Nishikawa K., Li H., Kawamura R., Osaka H., Wang Y.L., Hara Y., Hirokawa T., Manago Y., Amano T., Noda M., Aoki S., Wada K. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 304:2003;176-183
195. Niwa J., Ishigaki S., Doyu M., Suzuki T., Tanaka K., Sobue G. A novel centrosomal ring-finger protein, dorfin, mediates ubiquitin ligase activity. Biochem. Biophys. Res. Commun. 281:2001;706-713
196. O'Farrell C., Pickford F., Vink L., McGowan E., Cookson M.R. Sequence conservation between mouse and human synphilin-1. Neurosci. Lett. 322:2002;9-12
197. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22:1999;123-144
198. Oliveira S.A., Scott W.K., Martin E.R., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Pahwa R., Stern M.B., Hiner B.C., Ondo W.G., Allen F.H. Jr., Scott B.L., Goetz C.G., Small G.W., Mastaglia F., Stajich J.M., Zhang F., Booze M.W., Winn M.P., Middleton L.T., Haines J.L., Pericak-Vance M.A., Vance J.M. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann. Neurol. 53:2003;624-629
199. Olney J.W., Collins R.C., Sloviter R.S. Excitotoxic mechanisms of epileptic brain damage. Adv. Neurol. 44:1986;857-877
200. Oluwatosin-Chigbu Y., Robbins A., Scott C.W., Arriza J.L., Reid J.D., Zysk J.R. Parkin suppresses wild-type alpha-synuclein-induced toxicity in SHSY-5Y cells. Biochem. Biophys. Res. Commun. 309:2003;679-684
201. Orth M., Tabrizi S.J. Models of Parkinson's disease. Mov. Disord. 18:2003;729-737
202. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B. Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19:1999;5782-5791
203. Paci C., Thomas A., Onofrj M. Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol. Sci. 22:2001;75-76
204. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723
205. Parker W.D. Jr., Swerdlow R.H. Mitochondrial dysfunction in idiopathic Parkinson disease. Am. J. Hum. Genet. 62:1998;758-762
206. Pendleton R.G., Parvez F., Sayed M., Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J. Pharmacol. Exp. Ther. 300:2002;91-96
207. Peng X.R., Jia Z., Zhang Y., Ware J., Trimble W.S. The septin CDCrel-1 is dispensable for normal development and neurotransmitter release. Mol. Cell. Biol. 22:2002;378-387
208. Perese D.A., Ulman J., Viola J., Ewing S.E., Bankiewicz K.S. A 6-hydroxydopamine-induced selective Parkinsonian rat model. Brain Res. 494:1989;285-293
209. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22:2002;3090-3099
210. Periquet M., Lucking C., Vaughan J., Bonifati V., Durr A., De Michele G., Horstink M., Farrer M., Illarioshkin S.N., Pollak P., Borg M., Brefel-Courbon C., Denefle P., Meco G., Gasser T., Breteler M.M., Wood N., Agid Y., Brice A. Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from founder effects. Am. J. Hum. Genet. 68:2001;617-626
211. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., Choi P., Wolozin B., Farrer M., Hardy J., Cookson M.R. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 36:2002;1007-1019
212. Polymeropoulos M.H. Genetics of Parkinson's disease. Ann. N. Y. Acad. Sci. 920:2000;28-32
213. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G., Sanges G., Stenroos E.S., Pho L.T., Schaffer A.A., Lazzarini A.M., Nussbaum R.L., Duvoisin R.C. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 274:1996;1197-1199
214. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047
215. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., Akram M. The Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76:2001;1265-1274
216. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 67:1995;631-647
217. Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M., Haass C., Schulz J.B. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 77:2001;1181-1184
218. Rawal N., Periquet M., Lohmann E., Lucking C.B., Teive H.A., Ambrosio G., Raskin S., Lincoln S., Hattori N., Guimaraes J., Horstink M.W., Dos Santos B.W., Brousolle E., Destee A., Mizuno Y., Farrer M., Deleuze J.F., De Michele G., Agid Y., Durr A., Brice A. New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism. Neurology. 60:2003;1378-1381
219. Reinhard J.F. Jr., Diliberto E.J. Jr., Viveros O.H., Daniels A.J. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc. Natl. Acad. Sci. U.S.A. 84:1987;8160-8164
220. Ren Y., Zhao J., Feng J. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J. Neurosci. 23:2003;3316-3324
221. Ribeiro C.S., Carneiro K., Ross C.A., Menezes J.R., Engelender S. Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J. Biol. Chem. 277:2002;23927-23933
222. Richardson P.J., Kase H., Jenner P.G. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. 18:1997;338-344
223. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175:2002;35-48
224. Riess O., Kruger R. Parkinson's disease - a multifactorial neurodegenerative disorder. J. Neural. Transm. Suppl. 56:1999;113-125
225. Rochet J.C., Conway K.A., Lansbury P.T. Jr. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry. 39:2000;10619-10626
226. Rochet J.C., Lansbury P.T. Jr. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10:2000;60-68
227. Rothman S.M., Olney J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19:1986;105-111
228. Saigoh K., Wang Y.L., Suh J.G., Yamanishi T., Sakai Y., Kiyosawa H., Harada T., Ichihara N., Wakana S., Kikuchi T., Wada K. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 23:1999;47-51
229. Saito Y., Kawashima A., Ruberu N.N., Fujiwara H., Koyama S., Sawabe M., Arai T., Nagura H., Yamanouchi H., Hasegawa M., Iwatsubo T., Murayama S. Accumulation of phosphorylated alpha-synuclein in aging human brain. J. Neuropathol. Exp. Neurol. 62:2003;644-654
230. Sampathu D.M., Giasson B.I., Pawlyk A.C., Trojanowski J.Q., Lee V.M. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am. J. Pathol. 163:2003;91-100
231. Satoh J.I., Kuroda Y. A putative polymorphic Val44Ala variation in the synphilin-1 gene is undetectable in Japanese sporadic Parkinson's disease patients. Eur. J. Neurol. 9:2002;15-18
232. Sawada H., Kohno R., Kihara T., Izumi Y., Sakka N., Ibi M., Nakanishi M., Nakamizo T., Yamakawa K., Shibasaki H., Yamamoto N., Akaike A., Inden M., Kitamura Y., Taniguchi T., Shimohama S. Proteasome mediates dopaminergic neuronal degeneration and its inhibition causes alpha-synuclein inclusions. J. Biol. Chem. 279:2004;10710-10719
233. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827
234. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1:1989;1269
235. Schinder A.F., Olson E.C., Spitzer N.C., Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J. Neurosci. 16:1996;6125-6133
236. Schlossmacher M.G., Frosch M.P., Gai W.P., Medina M., Sharma N., Forno L., Ochiishi T., Shimura H., Sharon R., Hattori N., Langston J.W., Mizuno Y., Hyman B.T., Selkoe D.J., Kosik K.S. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160:2002;1655-1667
237. Schmidt N., Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural. Transm. 108:2001;1263-1282
238. Schulz J.B., Matthews R.T., Muqit M.M., Browne S.E., Beal M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64:1995;936-939
239. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125:2001;109-125
240. Seidler A., Hellenbrand W., Robra B.P., Vieregge P., Nischan P., Joerg J., Oertel W.H., Ulm G., Schneider E. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology. 46:1996;1275-1284
241. Seo J.H., Rah J.C., Choi S.H., Shin J.K., Min K., Kim H.S., Park C.H., Kim S., Kim E.M., Lee S.H., Lee S., Suh S.W., Suh Y.H. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 16:2002;1826-1828
242. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179:2003;9-16
243. Shi Q., Tao E. An Ile93Met substitution in the UCH-L1 gene is not a disease-causing mutation for idiopathic Parkinson's disease. Chin. Med. J. (Engl.). 116:2003;312-313
244. Shimizu K., Matsubara K., Ohtaki K., Shiono H. Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture. Neurosci. Res. 46:2003;523-532
245. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25:2000;302-305
246. Shimura H., Hattori N., Kubo S., Yoshikawa M., Kitada T., Matsumine H., Asakawa S., Minoshima S., Yamamura Y., Shimizu N., Mizuno Y. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45:1999;668-672
247. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-269
248. Singleton A., Gwinn-Hardy K., Sharabi Y., Li S.T., Holmes C., Dendi R., Hardy J., Singleton A., Crawley A., Goldstein D.S. Association between cardiac denervation and parkinsonism caused by {alpha}-synuclein gene triplication. Brain. 127:2004;768-772
249. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science. 302:2003;841-ja
250. Smith T.S., Swerdlow R.H., Parker W.D. Jr., Bennett J.P. Jr. Reduction of MPP(+)-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. NeuroReport. 5:1994;2598-2600
251. Solano S.M., Miller D.W., Augood S.J., Young A.B., Penney J.B. Jr. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann. Neurol. 47:2000;201-210
252. Specht C.G., Schoepfer R. Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci. 2:2001;11
253. Speciale S. MPTP. Insights into Parkinsonian neurodegeneration. Neurotoxicol. Teratol. 24:2002;607
254. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6469-6473
255. Stichel C.C., Augustin M., Kuhn K., Zhu X.R., Engels P., Ullmer C., Lubbert H. Parkin expression in the adult mouse brain. Eur. J. Neurosci. 12:2000;4181-4194
256. Subramaniam S., Strelau J., Unsicker K. Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways. J. Biol. Chem. 278:2003;8904-8912
257. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett J.P. Jr., Davis R.E., Parker W.D. Jr. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40:1996;663-671
258. Takahashi H., Wakabayashi K. The cellular pathology of Parkinson's disease. Neuropathology. 21:2001;315-322
259. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., Jackson-Lewis V., Przedborski S., Uhl G.R. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. U.S.A. 94:1997;9938-9943
260. Takahashi R., Imai Y. Pael receptor, endoplasmic reticulum stress, and Parkinson's disease. J. Neurol. 250:2003;III25-III29
261. Takahashi R.N., Rogerio R., Zanin M. Maneb enhances MPTP neurotoxicity in mice. Res. Commun. Chem. Pathol. Pharmacol. 66:1989;167-170
262. Tanaka K., Suzuki T., Chiba T., Shimura H., Hattori N., Mizuno Y. Parkin is linked to the ubiquitin pathway. J. Mol. Med. 79:2001;482-494
263. Tanji K., Toki T., Tamo W., Imaizumi T., Matsumiya T., Mori F., Takahashi H., Satoh K., Wakabayashi K. Glycogen synthase kinase-3beta phosphorylates synphilin-1 in vitro. Neuropathology. 23:2003;199-202
264. Tanner C.M., Langston J.W. Do environmental toxins cause Parkinson's disease? A critical review. Neurology. 40:1990;17-30
265. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 77:1997;1037-1048
266. Tatton W.G., Chalmers-Redman R., Brown D., Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53(Suppl. 3):2003;S61-S70
267. Thiffault C., Langston J.W., Di Monte D.A. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res. 885:2000;283-288
268. Thiruchelvam M., Brockel B.J., Richfield E.K., Baggs R.B., Cory-Slechta D.A. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res. 873:2000;225-234
269. Thiruchelvam M., Richfield E.K., Goodman B.M., Baggs R.B., Cory-Slechta D.A. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. NeuroToxicology. 23:2002;621-633
270. Thomas A., Iacono D., Luciano A.L., Armellino K., Di Iorio A., Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 75:2004;141-143
271. Tompkins M.M., Basgall E.J., Zamrini E., Hill W.D. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am. J. Pathol. 150:1997;119-131
272. Tompkins M.M., Hill W.D. Contribution of somal Lewy bodies to neuronal death. Brain Res. 775:1997;24-29
273. Touchman J.W., Dehejia A., Chiba-Falek O., Cabin D.E., Schwartz J.R., Orrison B.M., Polymeropoulos M.H., Nussbaum R.L. Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res. 11:2001;78-86
274. Tritschler H.J., Packer L., Medori R. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Biochem. Mol. Biol. Int. 34:1994;169-181
275. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418
276. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11282-11286
277. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5:1968;107-110
278. Ungerstedt U. 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol. Ther. B. 2:1976;37-40
279. Uversky V.N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21:2003;211-234
280. Uversky V.N., Li J., Fink A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 500:2001;105-108
281. Valente E.M., Bentivoglio A.R., Dixon P.H., Ferraris A., Ialongo T., Frontali M., Albanese A., Wood N.W. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68:2001;895-900
282. Valente E.M., Brancati F., Caputo V., Graham E.A., Davis M.B., Ferraris A., Breteler M.M., Gasser T., Bonifati V., Bentivoglio A.R., De Michele G., Durr A., Cortelli P., Filla A., Meco G., Oostra B.A., Brice A., Albanese A., Dallapiccola B., Wood N.W. PARK6 is a common cause of familial parkinsonism. Neurol. Sci. 23(Suppl. 2):2002;S117-S118
283. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20:2000;6021-6029
284. van der Walt J.M., Nicodemus K.K., Martin E.R., Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Haines J.L., Koller W.C., Lyons K., Pahwa R., Stern M.B., Colcher A., Hiner B.C., Jankovic J., Ondo W.G., Allen F.H. Jr., Goetz C.G., Small G.W., Mastaglia F., Stajich J.M., McLaurin A.C., Middleton L.T., Scott B.L., Schmechel D.E., Pericak-Vance M.A., Vance J.M. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am. J. Hum. Genet. 72:2003;804-811
285. Van Duijn C.M., Dekker M.C., Bonifati V., Galjaard R.J., Houwing-Duistermaat J.J., Snijders P.J., Testers L., Breedveld G.J., Horstink M., Sandkuijl L.A., van Swieten J.C., Oostra B.A., Heutink P. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am. J. Hum. Genet. 69:2001;629-634
286. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP. J. Neurochem. 74:2000;721-729
287. Wakabayashi K., Engelender S., Tanaka Y., Yoshimoto M., Mori F., Tsuji S., Ross C.A., Takahashi H. Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathol. (Berl.). 103:2002;209-214
288. Wakabayashi K., Engelender S., Yoshimoto M., Tsuji S., Ross C.A., Takahashi H. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47:2000;521-523
289. Wakabayashi K., Hayashi S., Kakita A., Yamada M., Toyoshima Y., Yoshimoto M., Takahashi H. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. (Berl.). 96:1998;445-452
290. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinsztein D.C. Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278:2003;25009-25013
291. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T. Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 35:1996;13709-13715
292. Wilkinson K.D., Deshpande S., Larsen C.N. Comparisons of neuronal (PGP 9.5) and non-neuronal ubiquitin C-terminal hydrolases. Biochem. Soc. Trans. 20:1992;631-637
293. Wilkinson K.D., Lee K.M., Deshpande S., Duerksen-Hughes P., Boss J.M., Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science. 246:1989;670-673
294. Wilson M.A., Collins J.L., Hod Y., Ringe D., Petsko G.A. The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 100:2003;9256-9261
295. Wintermeyer P., Kruger R., Kuhn W., Muller T., Woitalla D., Berg D., Becker G., Leroy E., Polymeropoulos M., Berger K., Przuntek H., Schols L., Epplen J.T., Riess O. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. NeuroReport. 11:2000;2079-2082
296. Wooten G.F., Currie L.J., Bennett J.P., Harrison M.B., Trugman J.M., Parker W.D. Jr. Maternal inheritance in Parkinson's disease. Ann. Neurol. 41:1997;265-268
297. Xia Y., Saitoh T., Ueda K., Tanaka S., Chen X., Hashimoto M., Hsu L., Conrad C., Sundsmo M., Yoshimoto M., Thal L., Katzman R., Masliah E. Characterization of the human alpha-synuclein gene: genomic structure, transcription start site, promoter region and polymorphisms. J. Alzheimers Dis. 3:2001;485-494
298. Yoshikawa T. Free radicals and their scavengers in Parkinson's disease. Eur. Neurol. 33:1993;60-68
299. Zarate-Lagunes M., Gu W.J., Blanchard V., Francois C., Muriel M.P., Mouatt-Prigent A., Bonici B., Parent A., Hartmann A., Yelnik J., Boehme G.A., Pradier L., Moussaoui S., Faucheux B., Raisman-Vozari R., Agid Y., Brice A., Hirsch E.C. Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes. J. Comp. Neurol. 432:2001;184-196
300. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Tortosa E.G., Del Ser T., Munoz D.G., De Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia. Ann. Neurol. 55:2004;164-173
301. Zhang J., Fitsanakis V.A., Gu G., Jing D., Ao M., Amarnath V., Montine T.J. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J. Neurochem. 84:2003;336-346
302. Zhang J., Hattori N., Leroy E., Morris H.R., Kubo S., Kobayashi T., Wood N.W., Polymeropoulos M.H., Mizuno Y. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat. Disord. 6:2000a;195-197
303. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U.S.A. 97:2000b;13354-13359
304. Zhou W., Schaack J., Zawada W.M., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res. 926:2002;42-50